HCAT
Health Catalyst, Inc. (HCAT) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
High current and quick ratios support near-term liquidity versus more levered healthcare peers, reducing refinancing pressure despite weak profitability.
Cash conversion cycle of 32.9 days indicates moderate working-capital efficiency, which is better than many hospital operators with longer cash collection lags.
Net debt to EBITDA is negative, implying net cash or minimal net leverage versus peers that rely more heavily on debt-funded expansion.
The company’s capital structure appears more flexible than highly levered peers, which can preserve operating resilience through reimbursement and utilization volatility.
Weaknesses
Return on invested capital of -21.1% shows capital is not earning its cost, leaving HCAT structurally weaker than profitable peers.
Debt to equity of 1.69 is elevated for a healthcare services provider, limiting balance-sheet optionality versus less levered competitors.
The absence of positive operating and gross margin disclosure alongside negative ROIC suggests weak underlying unit economics relative to peers with steadier margins.
A 32.9-day cash conversion cycle still ties up working capital, making HCAT less efficient than peers with faster cash realization and lower funding needs.
Opportunities
If reimbursement and utilization improve, HCAT has operating leverage because small margin gains can translate into outsized returns from a currently depressed base.
The strong liquidity position provides room to fund process improvements or selective expansion more easily than peers constrained by tighter working capital.
Lower net leverage than many peers can support strategic flexibility, allowing the company to absorb temporary volatility while competitors face covenant pressure.
Any sustained improvement in capital efficiency would be more visible at HCAT than at mature peers, because current returns are starting from a weak baseline.
Threats
Persistent negative ROIC raises the risk that HCAT continues to destroy value while peers with positive returns compound capital more effectively.
Higher debt-to-equity than many healthcare peers increases sensitivity to rate pressure and earnings volatility, even with current liquidity coverage.
If reimbursement or labor costs worsen, HCAT’s weak profitability could lag peers that have more diversified revenue or stronger margin buffers.
Working-capital needs remain meaningful, so slower collections or payer mix deterioration could strain cash generation faster than at more efficient competitors.
Overall Score
HCAT’s peer positioning is constrained by deeply negative capital returns and elevated leverage, while liquidity and net cash characteristics only partially offset the structural कमजोरी.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Health Catalyst, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
